polyethylene glycol 3350 (miralax)

08/01/2005 - "PEG 3350 relieved constipation in most treated study subjects. "
04/01/2004 - "PEG 3350 is an effective and well-tolerated treatment choice for pediatric constipation, especially as an adjunct to education and behavioral training. "
07/01/2011 - "Published reports of clinical trials involving polyethylene glycol 3350, together with published articles examining the epidemiology, demographics, etiology, evaluation, and management of chronic constipation, were identified in a literature search through November 2009 using PubMed. "
01/01/2022 - "This multicenter, double-blind, placebo-controlled, parallel-group trial included adults with chronic idiopathic constipation randomized to polyethylene glycol 3350 17 g (n = 204) or placebo (n = 100) once daily for 24 weeks. "
05/06/2016 - "Polyethylene glycol 3350 in occasional constipation: A one-week, randomized, placebo-controlled, double-blind trial."

09/01/2002 - "The 3-day administration of PEG 3350 is safe and effective in the treatment of childhood fecal impaction at doses of 1 and 1.5 g/kg per day."
09/01/2002 - "Dose response of PEG 3350 for the treatment of childhood fecal impaction."
09/01/2002 - "This was a prospective, double-blind, parallel, randomized study of 4 doses of PEG 3350; 0.25 g/kg per day, 0.5 g/kg per day, 1 g/kg per day, 1.5 g/kg per day, given for 3 days in children with constipation for >3 months and evidence of fecal impaction. "
09/01/2002 - "To investigate the efficacy and safety of polyethylene glycol (PEG) 3350 in the treatment of childhood fecal impaction. "
02/01/2012 - "This study aimed to compare efficacy of enema versus polyethylene glycol (PEG) 3350 for pediatric fecal impaction treatment. "

10/01/2019 - "Relative Efficacy of Naloxegol and Polyethylene Glycol 3350 in Opioid-Induced Constipation."
01/01/2019 - "A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation."
10/01/1997 - "Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial."
01/01/2019 - "To determine patient preference for treating opioid-induced constipation (OIC) using naloxegol or polyethylene glycol (PEG) 3350 in patients receiving opioids for noncancer pain. "

11/01/2003 - "Long-term efficacy of polyethylene glycol 3350 for the treatment of chronic constipation in children with and without encopresis."
11/01/2003 - "Seventy-four children (43 with chronic constipation, 31 with constipation and encopresis) treated with polyethylene glycol 3350 (PEG) for longer than 3 months were studied to assess long-term efficacy. "
07/01/2003 - "Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children."
09/01/2001 - "Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children."
11/01/2004 - "A significant increase in defecation frequency (PEG 3350: 3 pre v 7 post treatment/week; lactulose: 3 pre v 6 post/week) and a significant decrease in encopresis frequency (PEG 3350: 10 pre v 3 post/week; lactulose: 8 pre v 3 post/week) was found in both groups (NS). "

05/01/2019 - "FDA adverse event reports revealed 53 additional cases of possible PEG 3350 anaphylaxis. "
01/01/2021 - "More data are needed on the value of skin prick testing to PEG (MiraLAX) in evaluating patients with mRNA COVID-19 vaccine anaphylaxis. "
11/01/2022 - "One patient with a significant history concerning of anaphylaxis in response to PEG had positive results of testing to identify allergy to PEG 2000, PEG 3350, and polysorbate 80 and was advised against vaccination. "
11/01/2023 - "Six patients had positive immediate intradermal tests with PEG 1500, all with severe PEG allergy: one with a near-fatal anaphylaxis after glucocorticoid injection containing PEG 3350 and five with systemic allergic reactions after mRNA vaccines containing PEG 2000 (Pfizer-BioNTech or Moderna). "
04/01/1996 - "To identify the cause of anaphylaxis in this patient, the vial lot was examined for the presence of endotoxin, and a checkerboard immunoblotting technique was used to test serum and/or plasma samples from the patient and mother for the presence of antibodies (IgA, IgG, IgE, and IgM) to Recombinate-related antigens (recombinant factor VIII, von Willebrand factor, human serum albumin, Chinese hamster ovary proteins, bovine serum albumin, mouse monoclonal anti-human factor VIII, polyethylene glycol 3350), and to ethylene oxide, the agent used to sterilize the infusion equipment. "